You are here

First In Human Study Of Increasing Oral Doses Of PF-04634817

Last updated on December 12, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male or female (of non-child bearing potential) subjects between 18 and 55
years of age.

- Body mass index of 17.5 to 30.5 kg/m2 and total body weight > 50kg.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of any clinically significant disease.

- Treatment with an investigational drug within 30 days of study start

- Use of prescription and non-prescription medicines within 7 days of study start

NCT01098877
Pfizer
Completed
First In Human Study Of Increasing Oral Doses Of PF-04634817

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Descriptive Information
Brief Title  ICMJE First In Human Study Of Increasing Oral Doses Of PF-04634817
Official Title  ICMJE A Double Blind, Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Pharmacokinetics (In The Fed And Fasted State), Safety And Toleration Of Single Oral Doses Of PF-04634817 In Healthy Volunteers
Brief Summary The study will evaluate the hypothesis that at doses and plasma concentrations which affect pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound is safe and well tolerated. It will also evaluate the hypothesis that the pharmacokinetic profile is robust and consistent with a once or twice a day therapeutic administration.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: PF-04634817 Placebo
    Oral solution, placebo, single dose
  • Drug: PF-04634817
    Oral solution, 1mg, single dose
  • Drug: PF-04634817
    Oral solution, 3mg, single dose
  • Drug: PF-04634817
    Oral solution, 10mg, single dose
  • Drug: PF-04634817
    Oral solution, 30mg, single dose
  • Drug: PF-04634817
    Oral solution, 100mg, single dose
  • Drug: PF-04634817
    Oral solution, 300mg, single dose
  • Drug: PF-04634817
    Oral solution, 600mg, single dose
  • Drug: PF-04634817
    Oral solution, 900mg, single dose
  • Drug: PF-04634817
    Oral solution, up to 900mg, single dose after food
  • Drug: PF-04634817 Placebo
    Oral solution, placebo, single dose after food
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Intervention: Drug: PF-04634817 Placebo
  • Experimental: Cohort 1, 1mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 1, 3mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 1, 10mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 2, 30mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 2, 100mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 2, 300mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 3, 600mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 3, 900mg
    Intervention: Drug: PF-04634817
  • Experimental: Cohort 3, up to 900mg (fed)
    Intervention: Drug: PF-04634817
  • Placebo Comparator: Cohort 3, placebo (fed)
    Intervention: Drug: PF-04634817 Placebo
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 1, 2010)
27
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2010
Actual Primary Completion Date September 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male or female (of non-child bearing potential) subjects between 18 and 55 years of age.
  • Body mass index of 17.5 to 30.5 kg/m2 and total body weight > 50kg.

Exclusion Criteria:

  • Evidence or history of any clinically significant disease.
  • Treatment with an investigational drug within 30 days of study start
  • Use of prescription and non-prescription medicines within 7 days of study start
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01098877
Other Study ID Numbers  ICMJE B1261002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date October 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now